$0.191
-0.120 (-62.91%)收盤時
- High
- 0.510
- Open
- 0.510
- VWAP
- 0.30
- Vol
- 8.44M
- Mkt Cap
- 30.86M
- Low
- 0.190
- Amount
- 2.51M
- EV/EBITDA, TTM
- 0.00
NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing its (SuperNK) SNK (super-activated) platform. SNK involves the infusion of one’s own activated NK cells into the body to improve immune system function, eliminate diseased or abnormal cells and prevent recurrence. SNK uses pure NK cells harvested from the patient’s blood, activated and infused back into the patient’s body. SNK has a therapeutic potential within the areas of cancer, autoimmune and neurodegenerative diseases. Autologous NK cell immunotherapy is a treatment that provides immune enhancement using pure NK cells harvested from a patient’s body. It is also focused on conducting clinical trials with its super-activated NK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
估值指標
事件時間軸
資訊
5.012-03GlobenewswireNKGen Biotech Appoints New Board Members to Boost Asia-Pacific Growth
9.007-21NASDAQ.COMNKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down
2.003-13Business InsiderBiotech Alert: Searches spiking for these stocks today
7.003-04NewsfilterNKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
7.003-04Business InsiderNKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split
NKGN FAQ — answered by Alphio AI
NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing its (SuperNK) SNK (super-activated) platform. SNK involves the infusion of one’s own activated NK cells into the body to improve immune system function, eliminate diseased or abnormal cells and prevent recurrence. SNK uses pure NK cells harvested from the patient’s blood, activated and infused back into the patient’s body. SNK has a therapeutic potential within the areas of cancer, autoimmune and neurodegenerative diseases. Autologous NK cell immunotherapy is a treatment that provides immune enhancement using pure NK cells harvested from a patient’s body. It is also focused on conducting clinical trials with its super-activated NK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。